Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
panitumumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR), acting as a pure antagonist by blocking ligand binding and inducing internalization of EGFR. This inhibits downstream signaling pathways involved in tumor cell proliferation, survival, and angiogenesis. Panitumumab is primarily indicated for metastatic colorectal cancer with wild-type RAS genes[2][6][8]. Paclitaxel is a chemotherapeutic agent classified as a taxane; it stabilizes microtubules and prevents their depolymerization, thereby inhibiting cell division and promoting apoptosis in rapidly dividing cancer cells[1]. Nab-paclitaxel (albumin-bound paclitaxel) is a formulation designed to enhance delivery to tumors via albumin-mediated transport mechanisms[5]. The combination of panitumumab with paclitaxel or nab-paclitaxel has been studied in clinical trials for various cancers.
- Brand names
- Abraxane
- Other names
- panitumumabpaclitaxelnab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on panitumumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on panitumumab + paclitaxel.